Pub. Date : 2002 Jul
PMID : 12114432
11 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 2 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 3 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 4 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 5 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 6 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 7 | PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 8 | Recent evidence indicates that Gemcitabine (Gem) may modulate ERCC1 nucleotide excision repair activity, and down-regulation of DNA repair activity by ERCC1 antisense RNA reportedly inhibits synergism of CDDP/Gem. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 9 | CONCLUSIONS: These data suggest that ERCC1 expression is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 10 | This result may reflect the impact of Gem and the requirement for ERCC1 expression for CDDP/Gem synergism or may be attributable to the relatively small patient sample size in this study. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 11 | Prospective studies of ERCC1 as a predictive marker for activity of CDDP-based regimens in NSCLC are warranted. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |